
In the NRG GY018 trial, the addition of pembrolizumab to standard-of-care chemotherapy followed by maintenance pembrolizumab demonstrated a reduction in risk of disease progression or death in patients with advanced or recurrent endometrial cancer.

In the NRG GY018 trial, the addition of pembrolizumab to standard-of-care chemotherapy followed by maintenance pembrolizumab demonstrated a reduction in risk of disease progression or death in patients with advanced or recurrent endometrial cancer.

The FDA released a draft guidance for drug sponsors of clinical trials in oncology, outlining its move toward requiring randomized controlled trials to grant accelerated approvals for most oncology therapeutics.

With little improvement in survival seen for patients with small cell lung cancer, investigators are now assessing novel agents that are shifting the treatment paradigm of extensive disease-small cell lung cancer.

Late-stage clinical trials are evaluating MDM2 inhibitors that target p53 in both solid tumors and hematologic malignancies.

Alexander Drilon, MD, discusses what to know when testing for NTRK gene fusions in patients with lung cancer.

In updated findings of the ENGOT-OV16/NOVA trial, final overall survival data of niraparib maintenance therapy showed a benefit for patients with recurrent ovarian cancer; however, mature data showed no significant benefit. In updated findings of the ENGOT-OV16/NOVA trial, final overall survival data of niraparib maintenance therapy showed a benefit for patients with recurrent ovarian cancer; however, mature data showed no significant benefit.

In an interview with Targeted Oncology, Jennifer Y. Wo, MD, highlighted emerging discussions in the metastatic colorectal cancer space, where targeted therapies play a role, and what the next steps for research include.

In an interview, Edwin Choy, MD, discussed the treatment landscape of GIST and recent changes to NCCN guidelines.

The phase 1b SOLAR trial which evaluated olaparib plus selumetinib in patients with RAS-mutated ovarian or endometrial cancer showed there to be a clinical benefit with the combination.


Among patients with newly diagnosed, advanced ovarian cancer, dose modifications to frontline niraparib maintenance therapy did not affect progression-free survival.

A correlation in total scores were seen between the gynecological cancer lymphedema questionnaire and the lower extremity lymphedema screening questionnaire, according to findings presented at the 2023 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

Next-generation CAR T cells, including 1928T2Z and WZTL-002, continue to be investigated for the treatment of patients with large B-cell lymphoma.

The phase 2 KGOG3046 is the first study to show survival outcomes with the dual checkpoint blockades, durvalumab and tremelimumab, combined with neoadjuvant chemotherapy for the treatment of patients with newly diagnosed advanced ovarian cancer.

John Diaz, MD, discusses some of the challenges with using targeted therapies in the ovarian cancer space.

Newer approaches for patients with relapsed/refractory multiple myeloma are moving away from chemoimmunotherapy and toward drugs with novel mechanisms of action.

An updated guideline and panel recommends treatment with sacituzumab govitecan for patients with HR-positive/HER2-negative metastatic breast cancer who are refractory to endocrine therapy.

In an interview with Targeted Oncology, Paul Richardson, MD, highlighted his presentation from the 4th Annual Miami Cancer Institute Global Summit on Immunotherapies for Hematologic Malignancies on updates and personalization of treatments for patients with multiple myeloma.

A patient who received AB8939, a microtubule inhibitor, in a phase 1 study, had a significant reduction in bone marrow blasts, showing its potential to treat drug-resistant acute myeloid leukemia.

The FDA noted that additional requirements are needed prior to the approval of ruxolitinib extended-release for patients with myelofibrosis, polycythemia vera, and graft-versus-host disease, in a complete response letter.

In an interview with Targeted Oncology, Robert J. Soiffer, MD, discussed relapse after transplant for patients with cancer and what is important to note moving forward with research.

Gene G. Finley, MD, provides advice to community oncologists who are treating patients with small cell lung cancer.

Clinical trials exploring regimens without ASCT consolidation in young patients with MCL are needed, and maintenance with rituximab should be considered for patients after first-line treatment with bendamustine plus rituximab and R-CHOP

Tirabrutinib has received orphan drug status from the FDA and is being studied in the phase 2 PROSPECT study for patients with primary central nervous system lymphoma.

The first orphan drug designation from the FDA has been received by FORE Biotherapeutics and for the FORE8394 program for patients with primary brain and central nervous system malignancies.

FDA approval may be looming for the combination of zolbetuximab and capecitabine/oxaliplatin after primary phase 3 results were presented during the March ASCO Virtual Plenary.

Laura A. Dawson, MD, FRCPC, discusses the NRG/RTOG 1112 study for patients with hepatocellular carcinoma which evaluated stereotactic body radiation therapy followed by sorafenib compared with sorafenib alone.

The FDA has okayed PD-1 inhibitor for the treatment of adults with advanced Merkel cell carcinoma.

In the largest study of CAR T-cell therapy, ZUMA-7, a key secondary end point was met with axicabtagene ciloleucel treatment in patients with relapsed or refractory large B-cell lymphoma.

In an interview with Targeted Oncology, Guenther Koehne, MD, PhD, provided an overview of The Summit of Americas on Immunotherapies for Hematologic Malignancies and some of the recent and exciting advances being seen in the hematology space.